AAPL   268.89 (+1.25%)
FB   200.74 (+0.69%)
MSFT   150.66 (+0.49%)
GOOGL   1,341.63 (+1.72%)
AMZN   1,753.29 (-0.42%)
CGC   18.61 (+0.05%)
NVDA   213.14 (+1.78%)
GE   10.97 (+1.67%)
TSLA   336.87 (+1.15%)
T   38.43 (+0.63%)
AMD   40.08 (+0.98%)
PRI   136.21 (+1.42%)
BAC   33.65 (+1.69%)
DIS   148.27 (+0.56%)
AAPL   268.89 (+1.25%)
FB   200.74 (+0.69%)
MSFT   150.66 (+0.49%)
GOOGL   1,341.63 (+1.72%)
AMZN   1,753.29 (-0.42%)
CGC   18.61 (+0.05%)
NVDA   213.14 (+1.78%)
GE   10.97 (+1.67%)
TSLA   336.87 (+1.15%)
T   38.43 (+0.63%)
AMD   40.08 (+0.98%)
PRI   136.21 (+1.42%)
BAC   33.65 (+1.69%)
DIS   148.27 (+0.56%)
AAPL   268.89 (+1.25%)
FB   200.74 (+0.69%)
MSFT   150.66 (+0.49%)
GOOGL   1,341.63 (+1.72%)
AMZN   1,753.29 (-0.42%)
CGC   18.61 (+0.05%)
NVDA   213.14 (+1.78%)
GE   10.97 (+1.67%)
TSLA   336.87 (+1.15%)
T   38.43 (+0.63%)
AMD   40.08 (+0.98%)
PRI   136.21 (+1.42%)
BAC   33.65 (+1.69%)
DIS   148.27 (+0.56%)
AAPL   268.89 (+1.25%)
FB   200.74 (+0.69%)
MSFT   150.66 (+0.49%)
GOOGL   1,341.63 (+1.72%)
AMZN   1,753.29 (-0.42%)
CGC   18.61 (+0.05%)
NVDA   213.14 (+1.78%)
GE   10.97 (+1.67%)
TSLA   336.87 (+1.15%)
T   38.43 (+0.63%)
AMD   40.08 (+0.98%)
PRI   136.21 (+1.42%)
BAC   33.65 (+1.69%)
DIS   148.27 (+0.56%)
Log in

NASDAQ:NXTC - NextCure Stock Price, Forecast & News

$51.38
+0.38 (+0.75 %)
(As of 12/6/2019 10:00 AM ET)
Today's Range
$49.65
Now: $51.39
$51.70
50-Day Range
$25.43
MA: $39.51
$82.89
52-Week Range
$13.86
Now: $51.39
$109.00
Volume9,663 shs
Average Volume250,698 shs
Market Capitalization$1.17 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for NextCure Inc.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NXTC
CUSIPN/A
CIKN/A
Phone240-399-4900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-22,800,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.17 billion
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable

Receive NXTC News and Ratings via Email

Sign-up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.


NextCure (NASDAQ:NXTC) Frequently Asked Questions

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

How were NextCure's earnings last quarter?

NextCure Inc (NASDAQ:NXTC) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02. The company had revenue of $1.58 million for the quarter, compared to the consensus estimate of $1.50 million. View NextCure's Earnings History.

When is NextCure's next earnings date?

NextCure is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for NextCure.

What price target have analysts set for NXTC?

5 analysts have issued 1-year price objectives for NextCure's shares. Their forecasts range from $44.00 to $87.00. On average, they anticipate NextCure's share price to reach $63.20 in the next twelve months. This suggests a possible upside of 23.9% from the stock's current price. View Analyst Price Targets for NextCure.

What is the consensus analysts' recommendation for NextCure?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NextCure.

Has NextCure been receiving favorable news coverage?

News coverage about NXTC stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. NextCure earned a news impact score of -1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for NextCure.

Who are some of NextCure's key competitors?

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Alibaba Group (BABA), Home Depot (HD), Honeywell International (HON), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), NVIDIA (NVDA), CVS Health (CVS), Mcdonald's (MCD), Amgen (AMGN) and Johnson & Johnson (JNJ).

When did NextCure IPO?

(NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

When did the company's lock-up period expire?

NextCure's lock-up period expired on Tuesday, November 5th. NextCure had issued 5,000,000 shares in its public offering on May 9th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Who are NextCure's major shareholders?

NextCure's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Matthews International Capital Management LLC (1.84%), State Street Corp (0.24%), Squarepoint Ops LLC (0.11%), Strs Ohio (0.03%) and Barclays PLC (0.01%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Institutional Ownership Trends for NextCure.

Which major investors are selling NextCure stock?

NXTC stock was sold by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC and Barclays PLC. View Insider Buying and Selling for NextCure.

Which major investors are buying NextCure stock?

NXTC stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC and Strs Ohio. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Insider Buying and Selling for NextCure.

How do I buy shares of NextCure?

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $51.01.

How big of a company is NextCure?

NextCure has a market capitalization of $1.16 billion. View Additional Information About NextCure.

What is NextCure's official website?

The official website for NextCure is http://www.nextcure.com/.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]


MarketBeat Community Rating for NextCure (NASDAQ NXTC)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about NextCure and other stocks. Vote "Outperform" if you believe NXTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NXTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel